Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT WIR Asia Tbk (WIRG.JK)
Jakarta, JK, ID
PT WIR ASIA Tbk, together with its subsidiaries, provides digital technology development services in Indonesia and internationally. The company operates through: Promotion and Advertising via an Interactive Platform; Software Application Development; Brand and IT Consulting; Transaction Commission via Inter Platform; Goods Sales via an Interactive Platform; and Digital Product Sales via an Interactive Platform segment. Its services include augmented reality-based technology solutions, interactive platform services, and a brand consultancy service. PT WIR ASIA Tbk was founded in 2009 and is based in Jakarta, Indonesia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.61% | -1.61% | -22.78% | -36.46% | -41.35% | -37.76% | -21.79% | -34.41% | -73.01% | -73.01% | -73.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+2.9% Q1'26: -24.4% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-0.8% Q1'26: +12.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+8.3% ★ Q1'26: -3.8% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+6.1% Q1'26: +8.8% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+12.4% ★ Q1'26: +13.8% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%-0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.51× ★ Q1'26: 0.71× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.69T
est: 1.79T (-5.2%)
|
2.49T
est: 2.52T (-1.0%)
|
2.60T
est: 2.63T (-1.1%)
|
2.68T
est: 2.80T (-4.5%)
|
3.04T
3.04T – 3.04T
+8.4% YoY
|
3.32T
3.32T – 3.32T
+9.1% YoY
|
| EBITDA |
92.63B
est: 107.04B (-13.5%)
|
144.13B
est: 303.05B (-52.4%)
|
134.26B
est: 316.75B (-57.6%)
|
266.23B
est: 337.70B (-21.2%)
|
366.01B
366.01B – 366.01B
+8.4% YoY
|
399.25B
399.25B – 399.25B
+9.1% YoY
|
| EBIT |
70.78B
est: 76.03B (-6.9%)
|
99.87B
est: 167.98B (-40.5%)
|
114.30B
est: 175.57B (-34.9%)
|
163.64B
est: 187.19B (-12.6%)
|
202.88B
202.88B – 202.88B
+8.4% YoY
|
221.30B
221.30B – 221.30B
+9.1% YoY
|
| Net Income |
41.38B
est: 35.82B (+15.5%)
|
69.02B
|
73.92B
est: 82.32B (-10.2%)
|
73.25B
est: 87.09B (-15.9%)
|
99.02B
99.02B – 99.02B
+13.7% YoY
|
109.75B
109.75B – 109.75B
+10.8% YoY
|
| SGA |
47.86B
est: 42.17B (+13.5%)
|
72.11B
est: 77.67B (-7.2%)
|
68.74B
est: 81.18B (-15.3%)
|
140.62B
est: 86.55B (+62.5%)
|
93.80B
93.80B – 93.80B
+8.4% YoY
|
102.32B
102.32B – 102.32B
+9.1% YoY
|
| EPS |
3.47
est: 3.00 (+15.7%)
|
5.80
|
6.19
est: 6.90 (-10.3%)
|
6.14
est: 7.30 (-15.9%)
|
8.30
8.30 – 8.30
+13.7% YoY
|
9.20
9.20 – 9.20
+10.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Budi Supratman | Head of Internal Audit | — | — |
| Ira Yuanita | Corporate Secretary | — | — |
| Stanislaus Aries Baju Nugroho | Chief Financial Officer, Director of Finance & Director | — | male |
| Stephen Budiman | President Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WIRG.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
